Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Dubos

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Respiratory Medicine and Research|May 17, 2020
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST studyC Fontaine-Delaruelle, J Mazières, J Cadranel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2019
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trialD Moro-Sibilot, N Cozic, M Pérol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAF<sup>V600</sup> and BRAF<sup>nonV600</sup> mutationsJ Mazieres, C Cropet, L Montané, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2019
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trialR S Herbst, P Baas, J L Perez-Gracia, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Respiratory Medicine and Research|May 17, 2020
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST studyC Fontaine-Delaruelle, J Mazières, J Cadranel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2019
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trialD Moro-Sibilot, N Cozic, M Pérol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAF<sup>V600</sup> and BRAF<sup>nonV600</sup> mutationsJ Mazieres, C Cropet, L Montané, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2019
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trialR S Herbst, P Baas, J L Perez-Gracia, et al.
Pageof 2